FDA broadened existing EUA of Lilly and Incyte’s baricitinib in patients hospitalized with COVID-19
On Jul. 29, 2021, Incyte announced the U.S. Food and Drug Administration (FDA) had broadened the Emergency Use…
On Jul. 29, 2021, Incyte announced the U.S. Food and Drug Administration (FDA) had broadened the Emergency Use…
On Jul. 2, 2021, the National Institutes of Health (NIH) announced funding five additional projects to identify ways…
On Jun. 7, 2021, the National Institutes of Health announced new findings published in JAMA Neurology that suggested…
On Jun. 4, 2021, The U.S. Food and Drug Administration (FDA) approved Chimerix’s Tembexa (brincidofovir) tablets and oral…
On Jun. 1, 2021, in a study of 11 medical-mystery patients, an international team of researchers led by…
On May 28, 2021, Pfizer and BioNTech announced that the Conditional Marketing Authorization for COMIRNATY in the European…
On May 26, 2021, GlaxoSmithKline and Vir Biotechnology announced the U.S. Food and Drug Administration (FDA) granted an…
On May 20, 2021, Merck announced V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity…
On May 19, 2021, Megan A. Cooper, MD, PhD, an associate professor of pediatrics at Washington University School…
On May 10, 2021, the National Institutes of Health (NIH) reported that an investigational gene therapy can safely…
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
On Apr. 29, 2021, researchers at the University of British Columbia (UBC) announced a study published in Cell…
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
On Apr. 16, 2021, the FDA revoked the emergency use authorization (EUA) that allowed for Eli Lilly’s investigational…
On Mar. 26, 2021, the U.S. Food and Drug Administration (FDA) approved the first in the world non-surgical…
On Mar. 16, 2021, research from the World Health Organization (WHO) and partners showed that the COVID-19 pandemic…
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab…
On Jan. 27, 2021, a U.S. Centers for Disease Control and Prevention (CDC) study found that the 2019-2020…
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
On Nov. 23, 2020, Viatris announced tentative approval from the FDA for a New Drug Application for pediatric…
On Nov. 21, 2020, the FDA issued an emergency use authorization (EUA) for Regeneron Pharmaceuticals’ casirivimab and imdevimab…
On Nov. 21, 2020, Regeneron announced that the antibody cocktail casirivimab and imdevimab administered together (also known as…
On Nov. 20, 2020, Eli Lilly announced that Health Canada had granted authorization under the Interim Order Respecting…
On Nov. 19, 2020, Eli Lilly and Incyte announced that the FDA had issued an Emergency Use Authorization…
On Nov. 9, 2020, the FDA granted Emergency Use Authorization (EUA) for Eli Lilly’s investigational neutralizing antibody bamlanivimab…
On Oct. 14, 2020, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and…
On Oct. 14, 2020, Regeneron announced that the U.S. Food and Drug Administration (FDA) had approved Inmazeb (atoltivimab,…
On Sept. 30, 2020, the National Institutes of Health (NIH) announced funding of a nationwide study to discover…